CooperVision, a world leader in myopia management for children, has announced new seven-year findings from its pivotal MiSight^® 1 day contact lens clinical trial. MiSight^® contact lens therapy studies have shown it is effective in slowing myopia progression in children by an average of 50% over six years.

• Myopia (shortsightedness) prevalence continues to grow and affect children worldwide.
• The data shows high satisfaction and acceptance of contact lens wear from children and their parents.
• 41% of children who wore MiSight contact lenses at the three year point had no significant change in prescription during the three year period compared to only 4% of those who did not.
• No rebound effect was noted at seven years, after one year of cessation.
• MiSight^® 1 day works for nearly all children with myopia. The study has shown that 90% of myopic eyes responded to the treatment.

The study is the world’s longest continuous running soft contact lens clinical trial for myopia management. CooperVision previously reported that MiSight® 1 day showed sustained slowing of myopia progression across multiple years of treatment. The seven year findings found that twelve months following treatment cessation, mean eye growth data indicated no evidence of rebound effect, meaning the myopia control gains are retained.

“Our unparalleled research clearly illustrates the tremendous potential of MiSight® 1 day for children of different ages and with different levels of myopia, regardless of when they start treatment. With these results, eye care professionals should be even more confident in prescribing MiSight® 1 day,” said Paul Chamberlain, BSc (Hons), MCOptom, the study’s principal investigator and CooperVision Director of Research Programs.

The latest data analysis goes even deeper to illustrate that the lenses offer a highly-desired proportional myopia control treatment effect. Abnormal eye length growth slowed by an average of approximately 50% with all tested ages (8-17). Because younger children’s myopia progresses faster than in older children, introducing MiSight® 1 day at the earliest opportunity may offer the maximum cumulative benefit over time.

“We saw these children grow into young adults during their seven years in the study. It is personally as well as professionally fulfilling to know that the benefits of treatment are retained. As MiSight® 1 day becomes more widely available and as myopia management becomes the standard of care, I hope other eye care professionals will experience that same joy,” said study investigator Nicola Logan, PhD, Professor of Optometry and Physiological Optics, Aston University.